middle.news
How Will Amplia’s A$27.5M Raise Propel Its Cancer Drug Trials?
10:01am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
How Will Amplia’s A$27.5M Raise Propel Its Cancer Drug Trials?
10:01am on Wednesday 23rd of July, 2025 AEST
Key Points
A$25 million institutional placement at $0.23 per share
A$2.5 million Share Purchase Plan launched with potential oversubscription
Funds to support ACCENT, AMPLICITY, kRAS, and ovarian cancer trials
Top-line ACCENT trial data expected late July/early August 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE